Department of Microbiology and Immunology, Center for Infectious Disease Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Department of Microbiology and Immunology, Center for Infectious Disease Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02273-19.
and are commensals of the gastrointestinal tract of most terrestrial organisms, including humans, and are major causes of health care-associated infections. Such infections are difficult or impossible to treat, as the enterococcal strains responsible are often resistant to multiple antibiotics. One intrinsic resistance trait that is conserved among and is cephalosporin resistance, and prior exposure to cephalosporins is one of the most well-known risk factors for acquisition of an enterococcal infection. Cephalosporins inhibit peptidoglycan biosynthesis by acylating the active-site serine of penicillin-binding proteins (PBPs) to prevent the PBPs from catalyzing cross-linking during peptidoglycan synthesis. For decades, a specific PBP (known as Pbp4 or Pbp5) that exhibits low reactivity toward cephalosporins has been thought to be the primary PBP required for cephalosporin resistance. We analyzed other PBPs and report that in both and , a second PBP, PbpA(2b), is also required for resistance; notably, the cephalosporin ceftriaxone exhibits a lethal effect on the Δ mutant. Strikingly, PbpA(2b) exhibits low intrinsic reactivity with cephalosporins and Unlike the Δ mutant, the Δ mutant exhibits a variety of phenotypic defects in growth kinetics, cell wall integrity, and cellular morphology, indicating that PbpA(2b) and Pbp5(4) are not functionally redundant and that PbpA(2b) plays a more central role in peptidoglycan synthesis. Collectively, our results shift the current understanding of enterococcal cephalosporin resistance and suggest a model in which PbpA(2b) and Pbp5(4) cooperate to coordinately mediate peptidoglycan cross-linking in the presence of cephalosporins.
和 是包括人类在内的大多数陆地生物胃肠道的共生菌,也是导致医疗保健相关感染的主要原因。由于负责的肠球菌菌株通常对多种抗生素具有耐药性,因此这些感染难以或不可能治疗。肠球菌和 之间存在一种内在的耐药特性,即头孢菌素耐药性,而先前接触头孢菌素是获得肠球菌感染的最著名的危险因素之一。头孢菌素通过酰化青霉素结合蛋白 (PBP) 的活性位点丝氨酸来抑制肽聚糖生物合成,从而阻止 PBP 在肽聚糖合成过程中催化交联。几十年来,一种对头孢菌素反应性低的特定 PBP(称为 Pbp4 或 Pbp5)被认为是头孢菌素耐药性所必需的主要 PBP。我们分析了其他 PBPs,并报告在 和 中,第二种 PBP,PbpA(2b),也需要抵抗;值得注意的是,头孢菌素头孢曲松对 Δ 突变体具有致命作用。引人注目的是,PbpA(2b)与头孢菌素的固有反应性低 与 相反,与 Δ 突变体相比,Δ 突变体在生长动力学、细胞壁完整性和细胞形态方面表现出多种表型缺陷,这表明 PbpA(2b)和 Pbp5(4)在功能上不是冗余的,并且 PbpA(2b)在肽聚糖合成中起着更核心的作用。总的来说,我们的研究结果改变了人们对肠球菌头孢菌素耐药性的现有认识,并提出了一个模型,其中 PbpA(2b)和 Pbp5(4)在头孢菌素存在下协同合作协调介导肽聚糖交联。